Regorafenib

Generic Name
Regorafenib
Brand Names
Stivarga
Drug Type
Small Molecule
Chemical Formula
C21H15ClF4N4O3
CAS Number
755037-03-7
Unique Ingredient Identifier
24T2A1DOYB
Background

Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

Indication

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...

Associated Conditions
Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
Associated Therapies
-
Clinical Trials
Related News

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Phase 2
Recruiting
Conditions
Gastrointestinal Stromal Tumors
Interventions
Drug: Regorafenib
First Posted Date
2023-10-17
Last Posted Date
2024-06-21
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT06087263
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

First Posted Date
2023-09-21
Last Posted Date
2024-10-16
Lead Sponsor
Neonc Technologies, Inc.
Target Recruit Count
134
Registration Number
NCT06047379
Locations
🇺🇸

Precision NextGen Oncology, Beverly Hills, California, United States

🇺🇸

Northwest Medical Specialties, Tacoma, Washington, United States

Regorafenib in Combination with Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Phase 2
Recruiting
Conditions
MSI-H Colorectal Cancer
Interventions
Drug: Regorafenib
Drug: Pembrolizumab
First Posted Date
2023-08-23
Last Posted Date
2024-10-02
Lead Sponsor
Ibrahim Halil Sahin
Target Recruit Count
154
Registration Number
NCT06006923
Locations
🇺🇸

AdventHealth Orlando, Orlando, Florida, United States

🇺🇸

Northwestern University, Evanston, Illinois, United States

🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 1 locations

TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

First Posted Date
2023-08-15
Last Posted Date
2023-08-15
Lead Sponsor
China Medical University, China
Target Recruit Count
45
Registration Number
NCT05993702

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

Phase 2
Recruiting
Conditions
Colorectal Cancer
Interventions
Drug: KN046
Drug: regorafenib
First Posted Date
2023-08-14
Last Posted Date
2023-10-26
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
98
Registration Number
NCT05985109
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

First Posted Date
2023-08-01
Last Posted Date
2023-08-01
Lead Sponsor
Fudan University
Target Recruit Count
101
Registration Number
NCT05970705
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Regorafenib Alone or in Combination With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer

First Posted Date
2023-07-27
Last Posted Date
2023-07-27
Lead Sponsor
Fudan University
Target Recruit Count
90
Registration Number
NCT05963490
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

First Posted Date
2023-07-27
Last Posted Date
2024-01-16
Lead Sponsor
Beijing YouAn Hospital
Target Recruit Count
84
Registration Number
NCT05962450
Locations
🇨🇳

Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China

Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)

First Posted Date
2023-06-12
Last Posted Date
2024-04-29
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT05900648

The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

First Posted Date
2023-05-26
Last Posted Date
2023-05-26
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
20
Registration Number
NCT05877001
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy